title: Topical dobesilate eye drops for ophthalmic primary pterygium.
abstract: Selective inhibition of fibroblast growth factor and vascular endothelial growth factor signalling pathways is effective in causing regression of pterygia. Prompt regression of fibrovascular mass and conjunctival angiogenesis was documented 2 weeks after topical administration of dobesilate eye drops twice daily. At 3-month follow-up, no recurrence was seen and no ocular irritation and burning were noted. The authors believe that this is the first known successful use of topical dobesilate in primary pterygium.
authors.affiliation: Research, Hospital Ramon y Cajal, Madrid, Spain. pedro.cuevas@hrc.es
authors.forename: Pedro
authors.initials: P
authors.lastname: Cuevas
authors.forename: Luis A
authors.initials: LA
authors.lastname: Outeiriño
authors.forename: Javier
authors.initials: J
authors.lastname: Angulo
authors.forename: Guillermo
authors.initials: G
authors.lastname: Giménez-Gallego
mesh_terms: D002123:Calcium Dobesilate / Q000627:therapeutic use*; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000627:therapeutic use*; D011625:Pterygium / Q000188:drug therapy*
chemical_list: D006490:Hemostatics; D009883:Ophthalmic Solutions; D002123:Calcium Dobesilate